Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XANAX vs FENTANYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.
Anxiety disorders (generalized anxiety disorder),Panic disorder with or without agoraphobia,Off-label: Premenstrual dysphoric disorder, anxiety associated with depression, chemotherapy-induced anticipatory nausea and vomiting
Anesthesia adjunct (induction and maintenance),Analgesia during anesthesia (e.g., for surgery, mechanical ventilation),Management of acute pain (e.g., procedural sedation),Treatment of breakthrough pain in opioid-tolerant patients (via transmucosal formulations),Patient-controlled analgesia (PCA),Epidural or intrathecal analgesia (off-label),Prehospital analgesia for trauma (off-label)
Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.
25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.
Terminal elimination half-life: 11.2 hours (range 6.3–26.9 hours). With repeated dosing, half-life may prolong slightly; clinical context: allows once-daily dosing for most patients.
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults; prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life.
Hepatic metabolism primarily via CYP3A4 to active metabolites (e.g., α-hydroxyalprazolam).
Fentanyl undergoes extensive hepatic metabolism primarily via CYP3A4 N-dealkylation to norfentanyl (inactive) and other minor metabolites. Approximately 75% of the dose is excreted as metabolites in urine (primarily norfentanyl) and about 9% in feces. Less than 7% is excreted unchanged in urine. The terminal half-life is 3–12 hours, influenced by factors such as hepatic function and age.
Renal: ~80% (mainly as glucuronide metabolites, <20% unchanged). Fecal: <7%.
Primarily hepatic metabolism to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for ~75% of the dose (10% unchanged), with ~9% excreted in feces.
80% bound to albumin.
~80–85% bound primarily to albumin and alpha-1-acid glycoprotein.
Vd: 0.71–1.26 L/kg (mean ~0.9 L/kg). Indicates moderate tissue distribution with accumulation in CNS.
Vd: 3–8 L/kg (mean ~4 L/kg), indicating extensive tissue distribution and high lipophilicity.
Oral: 80–90% (immediate-release). Rectal: ~90%. Intramuscular: ~90%.
Transdermal: ~92%; Transmucosal (buccal): ~50%; Oral transmucosal lozenge: ~33%; Intranasal: ~50–70%; Oral (swallowed): very low due to first-pass metabolism (~30% but variable).
No specific GFR-based guidelines; use caution in severe renal impairment (Cr Cl <30 m L/min). Consider dose reduction or increased dosing interval due to prolonged half-life. Avoid in dialysis patients due to lack of dosing studies.
GFR 30-50: use with caution, consider dose reduction by 25-50%; GFR <30: avoid or initiate at 50% of usual dose and titrate slowly; anuric patients: significant accumulation, consider alternative.
Child-Pugh Class A: No adjustment recommended. Child-Pugh Class B: Reduce dose by 50% of normal starting dose. Child-Pugh Class C: Avoid use (no established safety).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with extreme caution, reduce dose by 75%.
Not approved for use in patients <18 years (safety and efficacy not established). Off-label for panic disorder in adolescents: starting dose 0.25-0.5 mg daily; titrate slowly based on response.
IV: 1-2 mcg/kg every 2-4 hours; transdermal: not recommended in opioid-naïve children <2 years, start at 12.5 mcg/h if >50 kg; transmucosal: 5-15 mcg/kg as single dose.
Initiate at 0.25 mg orally 2-3 times daily (lower starting dose). Titrate cautiously due to increased sensitivity and risk of falls/cognitive impairment. Maximum recommended dose: 2 mg/day in divided doses.
Start at 50% of usual adult dose, titrate cautiously by 25% increments; avoid transdermal in opioid-naïve elderly; monitor for respiratory depression and cognitive impairment.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF MEDICATION ERRORS (especially with transmucosal formulations).
Dependence and withdrawal reactions (including seizures) with abrupt discontinuation,Risk of abuse, misuse, and addiction,Concomitant use with CNS depressants increases risk of respiratory depression,Suicidal thinking and behavior,Activation of mania/hypomania in patients with bipolar disorder,Use in patients with narrow-angle glaucoma,Elderly and debilitated patients: increased sensitivity and risk of falls
Life-threatening respiratory depression: risk dose-dependent; monitor respiratory function, especially during initiation and dose escalation.,Addiction, abuse, and misuse: can occur even at recommended doses; screen patients for risk.,Neonatal opioid withdrawal syndrome: prolonged use during pregnancy can result in withdrawal in the newborn.,Interaction with CNS depressants: concomitant use with benzodiazepines or alcohol may cause profound sedation, respiratory depression, coma, and death.,Accidental exposure: especially with transdermal patches; can be fatal.,Risks from use in patients with head injury or increased intracranial pressure: may obscure neurological signs.,Severe hypotension: in patients with compromised blood volume or concomitant use of drugs that depress blood pressure.,Bradycardia and heart block: use with caution in patients with bradyarrhythmias.,Seizures: may exacerbate seizure disorders.,Serotonin syndrome: when used with serotonergic drugs.,Adrenal insufficiency: with prolonged use.,Severe injection site reactions: with injectable formulations.,Risk of medication errors: especially with different formulations (e.g., transdermal vs. transmucosal).
Hypersensitivity to alprazolam or other benzodiazepines,Acute narrow-angle glaucoma,Concurrent use of ketoconazole or itraconazole (strong CYP3A4 inhibitors),Pregnancy (especially first trimester) and breastfeeding (risk of neonatal sedation/withdrawal)
Hypersensitivity to fentanyl or any component of the formulation,Significant respiratory depression (in unmonitored settings or without resuscitative equipment),Acute or severe bronchial asthma,Paralytic ileus (known or suspected),Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy,Use in opioid-naive patients for transmucosal immediate-release fentanyl (due to risk of fatal respiratory depression),Acute abdomen (relative contraindication; may obscure diagnosis)
Grapefruit and grapefruit juice may increase serum concentrations of alprazolam; avoid concurrent use. Alcohol consumption should be avoided due to additive CNS depression. High-fat meals may delay absorption but do not significantly alter overall exposure.
Avoid grapefruit and grapefruit juice as they can increase fentanyl levels via CYP3A4 inhibition. No other significant food interactions. Maintain adequate hydration to prevent constipation.
First trimester: Increased risk of oral clefts; second and third trimesters: Risk of floppy infant syndrome, withdrawal, and CNS depressant effects.
First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near term may cause respiratory depression and neonatal abstinence syndrome.
Xanax is excreted in breast milk; M/P ratio 0.36. Avoid due to potential sedative effects on the infant.
Fentanyl is excreted into breast milk. Milk-to-plasma ratio is approximately 0.4. Avoid use in lactating women who are poor metabolizers or receive high doses due to risk of infant sedation and respiratory depression.
Increased clearance and decreased plasma protein binding may require dose adjustment; use lowest effective dose.
Clearance of fentanyl is increased during pregnancy, particularly in the third trimester. Dose adjustments may be required; consider increasing dose or frequency. Monitor for efficacy and adjust as needed.
Avoid abrupt discontinuation due to risk of withdrawal seizures; taper dose by 0.5 mg every 3 days. Use with caution in elderly due to increased fall risk and cognitive impairment. Onset of action is rapid (15-30 minutes) making it suitable for panic attacks. Contraindicated in narrow-angle glaucoma and severe hepatic impairment. Monitor for respiratory depression when co-prescribed with opioids.
Fentanyl is 50-100 times more potent than morphine. Due to high lipophilicity, onset of analgesia is rapid (within 30 seconds IV) but duration is short. Avoid bolus dosing in opioid-naive patients due to risk of chest wall rigidity. Transdermal patches are not indicated for acute pain due to slow onset and prolonged effect. Monitor for respiratory depression, especially in elderly and those with sleep apnea. Tolerance and physical dependence develop with chronic use. Naloxone is the reversal agent.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop taking suddenly as this can cause serious withdrawal symptoms including seizures; your doctor will wean you off gradually.,Avoid alcohol and other central nervous system depressants while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness or dizziness.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Store at room temperature away from moisture and heat, out of reach of children.
Do not drive or operate heavy machinery until you know how fentanyl affects you.,Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Avoid alcohol and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Store fentanyl patches and other formulations safely out of reach of children and pets; used patches should be folded and flushed down toilet.,Do not share this medication with others; it can cause fatal overdose.,Seek emergency medical help if you experience slow/shallow breathing, extreme drowsiness, or difficulty waking up.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.
No interactions on record
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XANAX vs FENTANYL, answered by our medical review team.
XANAX is a Benzodiazepine that works by Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.. FENTANYL is a Opioid Agonist that works by Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XANAX and FENTANYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XANAX is: Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.. The standard adult dose of FENTANYL is: 25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XANAX and FENTANYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XANAX is classified as Category C. First trimester: Increased risk of oral clefts; second and third trimesters: Risk of floppy infant syndrome, withdrawal, and CNS depressant effects.. FENTANYL is classified as Category D/X. First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.